Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazine SCHEMBL27892138 | 0.96 | NCF1 (0.52) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL84436 | 0.86 | MAPT (0.52) | NCF1HTR1AMAPTKDM4ECYP1A2 | |
| SCHEMBL30994907 | 0.86 | MAPT (0.52) | NCF1HTR1AMAPTKDM4ECYP1A2 | |
| SCHEMBL1496289 | 0.84 | NCF1 (0.47) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL264120 | 0.84 | NCF1 (0.52) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL14120837 | 0.84 | NCF1 (0.52) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL9576579 | 0.84 | NCF1 (0.47) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL1496311 | 0.84 | NCF1 (0.47) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL14122720 | 0.84 | NCF1 (0.52) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL14431011 | 0.84 | NCF1 (0.47) | NCF1LOXL2HTR1AADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 623 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118931996-A | Method for preparing high-purity glucopentasaccharide | 山东国力生物科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| CN-112939857-A | Synthetic method of alkylated quinoline compound | 中国科学院大连化学物理研究所 | 2021-06-11 | — | — | CN | claimed |
| US-20250186646-A1 | Use of Volatile Compositions to Limit or Eliminate Perception of Fecal Malodour | FIRMENICH SA (CH) | 2025-06-12 | — | — | US | disclosed |
| CN-119562995-A | Polysiloxane-based intumescent coating composition | 汉伯公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2025036155-A1 | PREPARATION METHOD FOR AND USE OF FUCOSE AND INTERMEDIATE THEREOF | 北京国科星联科技有限公司 | 2025-02-20 | — | — | WO | disclosed |
| EP-4218837-B1 | VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE PERCEPTION OF FECAL MALODOUR | FIRMENICH & CIE (CH) | 2024-11-27 | — | — | EP | disclosed |
| CN-118931996-A | Method for preparing high-purity glucopentasaccharide | 山东国力生物科技有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20240301319-A1 | PERFUMING COMPOSITIONS | FIRMNICH SA (CH) | 2024-09-12 | — | — | US | disclosed |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| US-12030878-B2 | Substituted indole ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030878-B2 | Substituted indole ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-7220735-B2 | Benzimidazolone histamine H3 antagonists | SCHERING CORPORATION (US) | 2007-05-22 | — | — | US | disclosed |
| US-7189728-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING, BV (NL) | 2007-03-13 | — | — | US | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
| WO-2006007700-A1 | HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006000085-A1 | HEPATITIS C INHIBITOR PEPTIDE ANALOGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-05 | — | — | WO | disclosed |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1481978-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | Mitsubishi Rayon Co., Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | IFNAR1, IFNG, IRF3 | NCF1 964/4885LOXL2 2182/4885HTR1A 2998/4885 |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | PIN4, IPO5, HLCS | NCF1 1088/4885LOXL2 3016/4885HTR1A 4327/4885 |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | PYGL, SERPINB1, PREP | NCF1 561/4885LOXL2 1198/4885HTR1A 3816/4885 |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | LPXN, SLC5A11, F12 | NCF1 2735/4885LOXL2 2232/4885HTR1A 2302/4885 |
| US-12030878-B2 | Substituted indole ether compounds | TLR7, TLR8, TLR1 | NCF1 252/4885LOXL2 2212/4885HTR1A 105/4885 |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | NCF1 3088/4885LOXL2 3270/4885HTR1A 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.